composite

Biotech Tools & CRO Core

members 5 weighting equal benchmark SPY

Equal-weight composite of the tools/CRO tier of the biotech capital-cycle thesis: quality laggards that monetize a reopened biotech funding window without single-trial risk — instruments (TMO, DHR), contract research (MEDP), bioprocessing (RGEN), and computational chemistry (SDGR).

Cumulative return since Jul 16 — both lines start at 0%, so the gap between them IS the out/under-performance. Hover for daily values.

	1D	7D	30D	3M	1Y
cohort	+0.6%	-2.0%	+9.8%	+41.0%	+12.8%
SPY	-0.5%	-0.1%	+4.0%	+4.9%	+21.4%
Δ	+1.1%	-2.0%	+5.8%	+36.1%	-8.7%

equal-weight · buy-and-hold from window start, no rebalancing · 3M+ windows are a current-roster backcast.

30D breadth 4/5 up

trend: 5 up · 0 flat · 0 down · avg RSI 62 · 100% above SMA200 · covered 5/5

contributors

RGEN+3.0pp+14.8%

SDGR+2.7pp+13.6%

MEDP+2.2pp+11.0%

TMO+2.0pp+10.0%

DHR-0.1pp-0.6%

RGEN $169.04 +1.3% +14.8% +62.2% +35.5% 72 in trend -3.8%

SDGR $17.40 -1.1% +13.6% +44.4% -14.4% 58 coming into play -24.4%

MEDP $597.12 +3.2% +11.0% +41.9% +28.8% 61 in trend -11.9%

TMO $585.51 -0.5% +10.0% +32.6% +17.5% 61 in trend -8.9%

DHR $202.63 +0.1% -0.6% +23.9% -3.6% 56 coming into play -16.2%